PRESS RELEASES

Date	Title
Jun 18, 2014	Ardelyx Announces Pricing of its Initial Public Offering
May 15, 2014	Ardelyx Receives $25 Million Milestone From AstraZeneca For Commencement Of Phase 2b Clinical Trial Of Tenapanor
Feb 24, 2014	Ardelyx Licenses NaP2b Phosphate Inhibitor Program for Kidney Disease to Sanofi in Deal Worth Up to $198 Million.
Jan 13, 2014	Ardelyx Receives $15 Million Milestone as Part of Ongoing Tenapanor Collaboration with AstraZeneca
Oct 8, 2012	AstraZeneca and Ardelyx Announce Worldwide Licensing Deal For NHE3 Inhibitor Programme For Complications Of Renal Disease, Including Diabetes-Induced Renal Disease.
May 24, 2012	Ardelyx will present at the 22nd European Meeting on Hypertension and Cardiovascular Protection in London (UK) April 26-29, 2012
Apr 1, 2012	"Non-systemic drugs: a critical review" published in Current Pharmaceutical Design
Aug 31, 2011	Ardelyx, Inc. Closes $30M Series B Financing
Aug 31, 2011	Ardelyx Appoints Mark Kaufmann to Chief Business Officer

FAQs

Email Alerts

Connect

Greater Boston
400 Fifth Avenue, Suite 210
Waltham, MA 02451

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Milwaukee
260 East Highland Avenue
Milwaukee, WI 53202

Phone: 617.675.ARDX (2739)

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com